AAD 2020:Phase 3 Clinically Proven IL-17A/IL-17F Monoantikizumab Treatment Psoriasis, Better Than IL-12/IL-23 Single Antiustekinumab

At the 2020 American Society of Dermatology (AAD) annual meeting, UCB released for the first time its Bimekizumab (IL-17A and IL-17F monotorther) clinical studies for adult patients with moderate to severe plaque psoriasisPhoto Source: Results showed better skin improvement in patients receiving bimekizumab in the Be VIVID and BE READY Phase III studies compared to patients receiving placebo and IL-12/IL-23 monoantibuta (ustekinumab)Both studies assessed the efficacy and safety of bimekizumab in adult patients with moderate to severe plaque-like psoriasis, and achieved a common primary endpoint, the psoriasis area and severity index (PASI 90), which improved by at least 90 percent, and the skin was almost completely transparent at week 16Emmanuel Caeymaex, Executive Vice President of UCB Immunology, said, "We are pleased to share the results of two bimekizumab Phase 3 studies (BE VIVID and BE READY)Most of the patients in these studies achieved fast and long-lasting skin removalThese positive results also support the inhibition of dual selective suppression of IL-17F and IL-17A than the inhibitory effect of IL-17A aloneBimekizumab is a humanized monoclonal IgG1 antibody that selectively inhibits IL-17A and IL-17F (the two key cytokines that drive the inflammatory process)IL-17F and IL-17A have overlapping biological properties and promote inflammation independently of IL-17AIn addition to the individual IL-17A inhibitory effects, the dual selective inhibition of IL-17A and IL-17F inhibits inflammation to a greater extentUCB plans to submit an application to regulators in 2020 for bimekizumab treatment for moderate and severe plaque psoriasis in adults